Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways

The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known regarding the effects of CPT on hypoxia-inducible...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvarajah, J, Nathawat, K, Moumen, A, Ashcroft, M, Carroll, V A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920935/
https://www.ncbi.nlm.nih.gov/pubmed/24136229
http://dx.doi.org/10.1038/cddis.2013.395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920935/
https://www.ncbi.nlm.nih.gov/pubmed/24136229
http://dx.doi.org/10.1038/cddis.2013.395

Ejemplares similares